PL2646464T3 - Przeciwnowotworowe białko fuzyjne - Google Patents
Przeciwnowotworowe białko fuzyjneInfo
- Publication number
- PL2646464T3 PL2646464T3 PL11790636T PL11790636T PL2646464T3 PL 2646464 T3 PL2646464 T3 PL 2646464T3 PL 11790636 T PL11790636 T PL 11790636T PL 11790636 T PL11790636 T PL 11790636T PL 2646464 T3 PL2646464 T3 PL 2646464T3
- Authority
- PL
- Poland
- Prior art keywords
- fusion protein
- anticancer fusion
- anticancer
- protein
- fusion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL393146A PL393146A1 (pl) | 2010-12-03 | 2010-12-03 | Przeciwnowotworowe białko fuzyjne |
| PL39459711 | 2011-04-18 | ||
| PCT/EP2011/071719 WO2012072815A1 (en) | 2010-12-03 | 2011-12-05 | Anticancer fusion protein |
| EP11790636.2A EP2646464B1 (en) | 2010-12-03 | 2011-12-05 | Anticancer fusion protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2646464T3 true PL2646464T3 (pl) | 2015-10-30 |
Family
ID=45065918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11790636T PL2646464T3 (pl) | 2010-12-03 | 2011-12-05 | Przeciwnowotworowe białko fuzyjne |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9161991B2 (pl) |
| EP (1) | EP2646464B1 (pl) |
| JP (1) | JP5759557B2 (pl) |
| KR (1) | KR101952460B1 (pl) |
| CN (1) | CN103237808B (pl) |
| AU (1) | AU2011334868B2 (pl) |
| BR (1) | BR112013013548B8 (pl) |
| CA (1) | CA2814595C (pl) |
| CY (1) | CY1116646T1 (pl) |
| DK (1) | DK2646464T3 (pl) |
| EA (1) | EA024452B1 (pl) |
| ES (1) | ES2545895T3 (pl) |
| HR (1) | HRP20150664T1 (pl) |
| HU (1) | HUE027068T2 (pl) |
| IL (1) | IL226207A (pl) |
| ME (1) | ME02224B (pl) |
| MX (1) | MX337436B (pl) |
| NZ (1) | NZ609216A (pl) |
| PH (1) | PH12013500714A1 (pl) |
| PL (1) | PL2646464T3 (pl) |
| PT (1) | PT2646464E (pl) |
| RS (1) | RS54057B1 (pl) |
| SG (2) | SG189370A1 (pl) |
| SI (1) | SI2646464T1 (pl) |
| SM (1) | SMT201500203B (pl) |
| WO (1) | WO2012072815A1 (pl) |
| ZA (1) | ZA201303449B (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL219845B1 (pl) * | 2011-01-05 | 2015-07-31 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
| EP2670426B1 (en) * | 2011-01-31 | 2017-05-10 | The General Hospital Corporation | Multimodal trail molecules and uses in cellular therapies |
| EP3473708B1 (en) | 2012-07-24 | 2021-01-27 | The General Hospital Corporation | Oncolytic virus therapy for resistant tumors |
| US9605074B2 (en) | 2012-08-30 | 2017-03-28 | The General Hospital Corporation | Multifunctional nanobodies for treating cancer |
| WO2014057436A2 (en) | 2012-10-10 | 2014-04-17 | Adamed Sp. Z O.O. | Anticancer conjugate |
| WO2014141094A1 (en) | 2013-03-14 | 2014-09-18 | Adamed Sp. Z O.O. | Anticancer conjugate |
| US10428132B2 (en) | 2015-02-11 | 2019-10-01 | West China Hospital, Sichuan University | Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof |
| CN106632682A (zh) * | 2015-08-04 | 2017-05-10 | 清华大学 | 融合蛋白ifn-elp及其应用 |
| CA3136602A1 (en) | 2019-04-15 | 2020-10-22 | Qwixel Therapeutics Llc | Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer |
| CA3174786A1 (en) | 2020-04-10 | 2021-10-14 | Sayantan Mitra | Activatable cytokine constructs and related compositions and methods |
| BR112023018735A2 (pt) | 2021-03-16 | 2023-11-28 | Cytomx Therapeutics Inc | Construtos de citocinas ativáveis mascarados e composições e métodos relacionados |
| KR102839482B1 (ko) | 2022-06-09 | 2025-07-25 | 제주대학교 산학협력단 | Trail을 포함하는 탈모 증상의 예방, 개선 또는 치료용 조성물 및 이의 용도 |
| KR20240068191A (ko) | 2022-11-10 | 2024-05-17 | 제주대학교 산학협력단 | 리모닌을 유효성분으로 포함하는 탈모 증상의 예방, 개선 또는 치료용 조성물 및 이의 용도 |
| CN116143945A (zh) * | 2022-12-09 | 2023-05-23 | 浙江大学杭州国际科创中心 | 一种趋化因子与免疫检查点抑制剂融合表达蛋白及其生产方法和应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| EP1666591B1 (en) | 1995-06-29 | 2011-03-23 | Immunex Corporation | Cytokine that induces apoptosis |
| WO2001095942A2 (en) * | 2000-06-09 | 2001-12-20 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates |
| IL154696A (en) | 2000-09-05 | 2008-11-03 | Biosight Ltd | Peptide conjugated anti-cancer prodrugs |
| DE10247755B4 (de) | 2002-10-14 | 2006-01-19 | Pfizenmaier, Klaus, Prof. Dr. | Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine |
| DE60336353D1 (de) | 2003-11-03 | 2011-04-21 | Beijing Sunbio Biotech Co Ltd | Rekombinantes protein mit krebsunterdrückender wirkung, sein codierendes gen und seine verwendung |
| ATE533058T1 (de) | 2005-08-16 | 2011-11-15 | Genentech Inc | Apoptosesensitivität gegenüber apo2l/trail mittels testen auf galnac-t14-expression in zellen/gewebe |
| WO2009002947A2 (en) | 2007-06-22 | 2008-12-31 | Affymax, Inc. | Compounds and peptides that bind the trail receptor |
| EP3321277B1 (en) * | 2007-07-10 | 2019-09-18 | Apogenix AG | Tnf superfamily collectin fusion proteins |
| EP2190861A4 (en) * | 2007-08-22 | 2011-03-30 | Univ California | ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE |
| GB0723059D0 (en) | 2007-11-23 | 2008-01-02 | Nat Univ Ireland | Improved cytokine design |
| GB0724532D0 (en) | 2007-12-17 | 2008-01-30 | Nat Univ Ireland | Trail variants for treating cancer |
| WO2009086132A2 (en) | 2007-12-20 | 2009-07-09 | University Of Southern California | Design of spacers to increase the expression of recombinant fusion proteins |
| TW200950778A (en) | 2008-05-14 | 2009-12-16 | Genentech Inc | Methods of using Apo2L/TRAIL to treat cancer |
| LT2010012A (lt) | 2010-02-10 | 2011-08-25 | Uab Profarma, , | Granulocitus stimuliuojančio baltymo linijiniai oligomerai su prailginta in vivo gyvavimo trukme |
-
2011
- 2011-12-05 SG SG2013027479A patent/SG189370A1/en unknown
- 2011-12-05 DK DK11790636.2T patent/DK2646464T3/en active
- 2011-12-05 PT PT117906362T patent/PT2646464E/pt unknown
- 2011-12-05 CA CA2814595A patent/CA2814595C/en active Active
- 2011-12-05 HR HRP20150664TT patent/HRP20150664T1/hr unknown
- 2011-12-05 EA EA201390820A patent/EA024452B1/ru unknown
- 2011-12-05 EP EP11790636.2A patent/EP2646464B1/en active Active
- 2011-12-05 WO PCT/EP2011/071719 patent/WO2012072815A1/en not_active Ceased
- 2011-12-05 JP JP2013541381A patent/JP5759557B2/ja active Active
- 2011-12-05 BR BR112013013548A patent/BR112013013548B8/pt active IP Right Grant
- 2011-12-05 KR KR1020137017194A patent/KR101952460B1/ko active Active
- 2011-12-05 ES ES11790636.2T patent/ES2545895T3/es active Active
- 2011-12-05 RS RS20150407A patent/RS54057B1/sr unknown
- 2011-12-05 SG SG10201509676UA patent/SG10201509676UA/en unknown
- 2011-12-05 PL PL11790636T patent/PL2646464T3/pl unknown
- 2011-12-05 CN CN201180057053.1A patent/CN103237808B/zh active Active
- 2011-12-05 US US13/989,969 patent/US9161991B2/en active Active
- 2011-12-05 HU HUE11790636A patent/HUE027068T2/en unknown
- 2011-12-05 PH PH1/2013/500714A patent/PH12013500714A1/en unknown
- 2011-12-05 SI SI201130524T patent/SI2646464T1/sl unknown
- 2011-12-05 NZ NZ609216A patent/NZ609216A/en unknown
- 2011-12-05 AU AU2011334868A patent/AU2011334868B2/en active Active
- 2011-12-05 MX MX2013006213A patent/MX337436B/es active IP Right Grant
- 2011-12-05 ME MEP-2015-89A patent/ME02224B/me unknown
-
2013
- 2013-05-07 IL IL226207A patent/IL226207A/en active IP Right Grant
- 2013-05-13 ZA ZA2013/03449A patent/ZA201303449B/en unknown
-
2015
- 2015-08-25 SM SM201500203T patent/SMT201500203B/xx unknown
- 2015-08-25 CY CY20151100743T patent/CY1116646T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201300677B (en) | Anticancer fusion protein | |
| ZA201404667B (en) | Anticancer fusion protein | |
| ZA201303449B (en) | Anticancer fusion protein | |
| GB201113558D0 (en) | Kraftfahrzeugkarosserie mit strukturverstarkter vorderrahmenanbindung | |
| SG10201500208SA (en) | Npp1 fusion proteins | |
| SMT201700300T1 (it) | "proteina di fusione anticancro | |
| ZA201405460B (en) | Anticancer fusion protein | |
| GB201116180D0 (en) | Kraftfahrzeug mit warnsystem | |
| IL226481A0 (en) | Enzymes@Maochim | |
| EP2698386B8 (en) | Fusion protein | |
| EP2657337A4 (en) | FUSION PROTEIN | |
| ZA201308597B (en) | Anticancer fusion protein | |
| PL2809342T3 (pl) | Peptyd dwufunkcyjny | |
| GB201016494D0 (en) | Polypeptide | |
| ZA201207425B (en) | Fusion protein | |
| EP2521787A4 (en) | IMPROVED PROTEIN EXPRESSION | |
| GB201016346D0 (en) | Connection means | |
| PL393146A1 (pl) | Przeciwnowotworowe białko fuzyjne | |
| GB201007955D0 (en) | Somatosatin fusion proteins | |
| HK1189602A (en) | Anticancer fusion protein | |
| GB201010202D0 (en) | Fusion polypeptides | |
| GB201107189D0 (en) | Fusion proteins | |
| GB201114701D0 (en) | Fusion proteins | |
| ZA201301851B (en) | Pharmaceutical combinations | |
| GB201104152D0 (en) | Fusion Polypeptide |